Syndromic Testing in Clinical Microbiology and Infectious Diseases: An Updated Review of Diagnostic Performance, Clinical and Healthcare Impact, and Emerging Developments

Syndromic testing, defined as the simultaneous nucleic acid amplification-based detection of multiple potential pathogens and antimicrobial resistance (AMR) determinants directly from clinical specimens, has transformed laboratory diagnosis of infectious diseases in the United States over the past two decades. In contrast to traditional microbiology workflows that rely on culture, phenotypic susceptibility testing, and sequential single-target assays with turnaround times of 24–72 h or longer, syndromic multiplex panels provide comprehensive pathogen identification within 1–5 h, enabling timely clinical decision-making, targeted antimicrobial therapy, and improved patient outcomes. In this review, the current landscape of FDA-cleared syndromic testing panels across seven major clinical syndromes is examined, including respiratory tract infections, pneumonia, bloodstream infections, gastrointestinal infections, meningitis/encephalitis, joint and bone infections, and global febrile/travel-related illnesses. For each syndrome, commercially available panels in the United States are summarized, with emphasis on diagnostic performance, clinical applications, and limitations. Available evidence demonstrates that syndromic testing, when integrated with institutional diagnostic and antimicrobial stewardship programs, can reduce time to optimal therapy and unnecessary antimicrobial use and, in selected settings, shorten hospital length of stay. A mortality benefit has been reported in some patient populations, particularly those with bloodstream infections. Nevertheless, rapid turnaround time and earlier pathogen identification do not necessarily translate into timely clinical action and improved patient outcomes. Challenges related to implementation and optimization of appropriate panel utilization, including evolving AMR epidemiology, dynamic and geographically variable pathogen distributions, the critical role of diagnostic and antimicrobial stewardship, and emerging developments for diagnosis and management of infectious disease, are also discussed.